Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The treatment of uterine leiomyosarcoma: Clinical outcomes of 18 cases and the effectiveness of chemotherapy
M. Matoda1,*, N. Takeshima1, H. Nomura1, M. Kino1, K. Omatsu1, H. Iwase1, K. Umayahara1, K. Takizawa1
1 Department of Gynecology, Cancer Institute Hospital, Ariake, Koutou-ku, Tokyo (Japan)
Eur. J. Gynaecol. Oncol. 2011, 32(6), 647–650;
Published: 10 December 2011
Purpose: To investigate clinical outcomes with respect to the effectiveness of chemotherapy in the treatment of uterine leiomyosarcoma. Methods: Study subjects were 18 patients with uterine leiomyosarcoma treated surgically at our hospital between February 1986 and December 2007. A chemotherapy regimen that combined ifosfamide, epirubicine, and cisplatin (IEP) was used as the main first-line chemotherapy. Results: FIGO disease stages were as follows: Stage I (n = 11), Stage II (n = 1), Stage III (n = 3), Stage IV (n = 3). Five-year overall survival of patients with Stage I-III disease was 65.3% (95% CI: 46.1-92.4%). None of patients with Stage IV disease survived for more than two years. Of seven patients who suffered advanced or recurrent disease, six received IEP; the response rate was 50%, one complete response and two partial responses. Conclusions: The combination of surgery and chemotherapy seems to be an acceptable treatment for uterine leiomyosarcoma. IEP may be an active regimen for this aggressive disease.